Rank probabilities of each treatment for different outcome measures based on the network meta-analysis
| BEV_DDP | DDP | Endo_DDP | Endo_LBP | Endo_NDP | LBP | NDP | |
| ORR | 0.33 | 0.00002 | 0.46 | 0.95 | 0.88 | 0.40 | 0.48 |
| DCR | 0.51 | 0.01 | 0.49 | 0.95 | 0.83 | 0.30 | 0.41 |
| QOL | 0.33 | 0.10 | 0.69 | 0.95 | / | 0.63 | 0.29 |
| Gastrointestinal effect | 0.32 | 0.28 | 0.18 | 0.47 | 0.56 | 0.80 | 0.89 |
| Myelosuppressive | 0.63 | 0.64 | 0.58 | 0.40 | 0.19 | 0.59 | 0.47 |
| Hypohepatia | 0.55 | 0.46 | 0.35 | 0.57 | 0.30 | 0.65 | 0.62 |
| G3-gastrointestinal effect | 0.40 | 0.35 | 0.19 | / | 0.54 | 0.71 | 0.81 |
| G3-myelosuppression | 0.39 | 0.48 | 0.37 | / | 0.32 | 0.64 | 0.81 |
| G3-hypohepatia | 0.21 | 0.30 | 0.72 | / | 0.45 | 0.57 | 0.74 |
The data are listed as SUCRA values (rank) and higher SUCRA values indicate better outcomes.
Bev_DDP, bevacizumab+cisplatin; DCR, disease control rate; Endo_DDP, endostar+cisplatin; Endo_LBP, endostar+lobaplatin; Endo_NDP, endostar+nedaplatin; G3, grade three or higher; ORR, objective response rate; QOL, quality of life; SUCRA, surface under the cumulative ranking area curve.